Outcome of poor response paediatric AML using early SCT

European Journal of Haematology

Volumn 90, Issue 3, 2013, Pages 187-194

  Wareham, Neval E ^a   Heilmann, Carsten ^a   Abrahamsson, Jonas ^b   Forestier, Erik ^c,d   Gustafsson, Britt ^e   Ha, Shau Yin ^f   Heldrup, Jesper ^g   Jahnukainen, Kirsi ^h   Jónsson, Ólafur G ⁱ   Lausen, Birgitte ^a   Palle, Josefine ^j   Zeller, Bernward ^k   Hasle, Henrik ^l  

^a University of Copenhagen   (Denmark)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f QUEEN MARY HOSPITAL   (Hong Kong)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^j UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

Acute myeloid leukaemia; Early stem cell transplantation; Poor response; Survival

Indexed keywords

ANTHRACYCLINE; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CHILD; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; INFANT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORGAN DONOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SCHOOL CHILD; SIBLING; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT RESPONSE; UMBILICAL CORD BLOOD; UNRELATED DONORS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYTARABINE; DISEASE-FREE SURVIVAL; EARLY MEDICAL INTERVENTION; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IDARUBICIN; INDUCTION CHEMOTHERAPY; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; MITOXANTRONE; MYELOABLATIVE AGONISTS; THIOGUANINE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84874001217     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12051     Document Type: Article

References (33)

1. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia:international progress and future directions. Leukemia 2005; 19: 2025-9.
2. Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. Areview on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010; 116: 2205-14.
3. Staffas A, Kanduri M, Hovland R, et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood 2011; 118: 5905-13.
4. Hasle H, Alonzo TA, Auvrignon A, et al. Monosomy 7 anddeletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood 2007; 109: 4641-7.
5. Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, HoviL, Jonmundsson G, Mellander L, Gustafsson G. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol 2003; 122: 217-25.
6. Klusmann JH, Reinhardt D, Zimmermann M, Kremens B,Vormoor J, Dworzak M, Creutzig U, Klingebiel T. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 2012; 97: 21-9.
7. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual diseasedirected therapy for childhood acute myeloid leukaemia:results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543-52.
8. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S,Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078-85.
9. Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003; 123: 243-52.
10. Rizzari C, Cazzaniga G, Coliva T, De AC, Conter V. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease. Expert Rev Anticancer Ther 2011; 11: 1391-401.
11. Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.J Clin Oncol 2011; 29: 1190-7.
12. Abrahamsson J, Forestier E, Heldrup J, Jahnukainen K, Jonsson OG, Lausen B, Palle J, Zeller B, Hasle H. Response guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol 2011; 29: 310-15.
13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA,Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-5.
14. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revisionof the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-51.
15. Hasle H, Abrahamsson J, Forestier E, Ha SY, Heldrup J, JahnukainenK, Jonsson OG, Lausen B, Palle J, Zeller B. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood 2012; 120: 978-84.
16. Ommen HB, Nyvold CG, Braendstrup K, Andersen BL,Ommen IB, Hasle H, Hokland P, Ostergaard M. Relapse prediction in acute myeloid leukaemia patients in completere mission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008; 141: 782-91.
17. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-9.
18. Creutzig U, Kaspers GJ. Revised recommendations of the International Working Group for diagnosis, standardization ofresponse criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2004; 22: 3432-3.
19. Basara N, Schulze A, Wedding U, et al. Early related or unrelatedhaematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009; 23: 635-40.
20. Lee DH, Kwon YJ, Lim J, Kim Y, Han K, Chung NG, Jeong DC, Cho B, Kim HK. Comparable outcomes of HLA-matched unrelated and HLA-identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission. Pediatr Transplant 2009; 13: 210-16.
21. Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13: 601-7.
22. Saarinen-Pihkala UM, Gustafsson G, Ringden O, Heilmann C,Glomstein A, Lonnerholm G, Abrahamsson J, Bekassy AN,Schroeder H, Mellander L. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 2001; 19: 3406-14.
23. Gustafsson A, Remberger M, Winiarski J, Ringden O. Unrelated bone marrow transplantation in children: outcome and a comparison with sibling donor grafting. Bone Marrow Transplant 2000; 25: 1059-65.
24. Remberger M, Mattsson J, Hentschke P, Aschan J, BarkholtL, Svennilson J, Ljungman P, Ringden O. The graft-versusleukaemia effect in haematopoietic stem cell transplantation using unrelated donors. Bone Marrow Transplant 2002; 30: 761-8.
25. Ringden O, Pavletic SZ, Anasetti C, et al. The graft-versusleukemia effect using matched unrelated donors is not superiorto HLA-identical siblings for hematopoietic stem cell transplantation. Blood 2009; 113: 3110-18.
26. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMTtrial. Blood 2005; 105: 410-19.
27. Locatelli F, Zecca M, Niemeyer C, et al. Role of allogeneic bone marrow transplantation for the treatment of myelodysplasticsyndromes in childhood. The European Working Group on Childhood Myelodysplastic Syndrome (EWOGMDS) and the Austria-Germany-Italy (AGI) Bone MarrowTransplantation Registry. Bone Marrow Transplant 1996; 18(Suppl 2): 63-8.
28. Ravandi F, Cortes J, Faderl S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010; 116: 5818-23.
29. Song KW, Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplant 2005; 36: 183-91.
30. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006; 24: 4499-506.
31. Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol 2011; 155: 366-76.
32. Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ.Long-term results of children with acute myeloid leukemia: areport of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005; 19: 2054-62.
33. Horan JT, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ,Ravindranath Y, Becton D, Smith FO, Woods WG. Impact ofdisease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol 2008; 26: 5797-801